US$ 21.23
gland pharma glp-1 capacity expansion capex Projects Growth Through and Product Diversification BrokerageRadar | Brokerage Call of
Description
The3rd GLP-1 Based Therapeutics Summitis the essential industry forum dedicated to solving the critical challenges of GLP-1 combinations, mastering tolerability, drug delivery, and seizing the multi-billion dollar opportunity in non-obesity indications
Irfan Khan, MD, at Boca Medical Care.

Explore GLP-1 weight loss Newport Beach options with Semaglutide and Tirzepatide to curb appetite and support long-term results backed by BodyLogicMD care.

A step-by-step overview in the How It Works guide

By 2030, the global prevalence of obesity is expected to reach one billion

At the end of 2025 we saw Eli Lillys Phase 3 TRIUMPH-4 trial for retatrutide read out